NCT01505868View on ClinicalTrials.gov

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

July 11, 2012

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaLymphadenopathyMetastatic Prostate CarcinomaProstate AdenocarcinomaProstate Carcinoma Metastatic in the BoneProstate Small Cell Carcinoma
Interventions
DRUG

Cabazitaxel

Given IV

DRUG

Carboplatin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01505868 - Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter